Business Context and Reporting Period
This Form 8-K Current Report from Karyopharm Therapeutics Inc. (KPTI) covers events occurring on March 24, 2026, and March 26, 2026, with the report filed on March 27, 2026. The filing details a private placement transaction and ongoing open market sales.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Gross proceeds of approximately $30 million from a transaction with RA Capital Management.
- Open Market Sale Proceeds: Net proceeds of approximately $19.8 million from the sale of 2,994,441 shares under an ATM agreement with Jefferies LLC.
- Capital Raised Total: Approximately $49.8 million in gross/net combined proceeds from the described March 2026 activities.
- Shares Outstanding: 22,543,316 shares of Common Stock following the transactions.
- Pre-funded Warrants: 4,005,556 pre-funded warrants outstanding.
- Liquidity Outlook: Management expects existing liquidity and operating cash flows to fund operations into late Q3 2026.
Material Changes and Transaction Details
The Company executed a Securities Purchase Agreement with RA Capital Management involving:
- Issuance of 1,030,354 shares of Common Stock at $6.785 per share.
- Issuance of pre-funded warrants for 3,391,164 shares at $6.7849 per warrant.
- Issuance of accompanying warrants for 4,421,518 shares with an exercise price of $10.00 per share.
Additionally, the Company sold 2,994,441 shares via its Open Market Sale Agreement, which included 1,100,844 shares previously disclosed on March 24, 2026.
Guidance, Outlook, and Risks
Management projects that the combination of existing cash, cash equivalents, investments, and net product revenue will sustain current operating plans through late in the third quarter of 2026. The filing does not provide specific revenue, profit, or margin figures for the period, nor does it detail specific risks beyond the standard implications of equity dilution inherent in the private placement and ATM sales.
Investor Verification Checklist
- Verify the exact net proceeds after deducting placement agent fees and offering expenses from the $30 million private placement.
- Confirm the total number of warrants outstanding (including the 4,421,518 new warrants) and their impact on potential future dilution.
- Review the Company's cash balance and burn rate to validate the "late Q3 2026" liquidity runway.
- Assess the market price of KPTI stock relative to the $6.785 issuance price and the $10.00 warrant exercise price.